Ingersoll Rand (India) DuPont analysis

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.75×0.75×0.74×0.75×0.74×
1.08×1.08×1.11×1.09×1.07×
22.9%22.9%24.2%22.5%19.9%
1.44×1.44×1.50×1.42×1.34×
1.62×1.62×1.53×1.47×1.49×
42.9%43.0%45.9%38.2%31.6%
41.8%41.8%45.0%38.4%31.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

INGERRAND₹3,935.90

Ingersoll Rand (India) Limited

· Capital Goods & Defence
₹ CrorePeersSWARAJENGYUKENROTOMcap ₹12,426 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.740.750.740.750.75
Interest Burden (Pretax/EBIT) ×1.071.091.111.081.08
EBIT Margin %19.9422.4624.2022.8622.88
Asset Turnover ×1.341.421.501.441.44
Financial Leverage (Assets/Equity) ×1.491.471.531.621.62
ROE (5-step product, year-end total equity) %31.6138.2145.9242.9642.91
ROE (owners' profit / average owners' equity) %31.6038.4044.9841.8041.80
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.